Raymond James Financial
ASMB icon

Raymond James Financial’s Assembly Biosciences ASMB Stock Holding History

Raymond James Financial’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,082
Closed -$445K – 5294
2025
Q4 		$445K Buy
+13,082
New +$421K ﹤0.01% 4344
2025
Q3 		– Sell
-250
Closed -$4.53K – 5071
2025
Q2 		$4.53K Buy
+250
New +$3.3K ﹤0.01% 6196

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Raymond James Financial's ASMB Position: Q1 2026 in Review

Raymond James Financial sold out of Assembly Biosciences (ASMB) in Q1 2026, closing a stake of 13,082 shares — an estimated $445K sold.

Raymond James Financial first reported a position in ASMB in Q2 2025 and held it in 2 quarters. The position peaked at $445K in Q4 2025. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Raymond James Financial reported no remaining Assembly Biosciences position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 13,082 Assembly Biosciences shares in Q1 2026, an estimated $445K.
  • Raymond James Financial first reported a position in Assembly Biosciences in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Assembly Biosciences position peaked at $445K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.